Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Steven R. Bird"'
3
The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study
Autor: Marco Metra, Piotr Ponikowski, Beth Davison Weatherley, Howard C. Dittrich, Michael M. Givertz, Steven R. Bird, Stephen S. Gottlieb, Barry M. Massie, Charlotte Jones-Burton, Christopher M. O'Connor, Kevin Gergich, Gad Cotter
Publikováno v: Journal of Cardiac Failure. 16:714-719
Background Worsening renal function (WRF) portends a poor prognosis, and recent deterioration in creatinine might identify patients with elevated intrarenal adenosine in whom adenosine A 1 antagonism may improve renal hemodynamics and function. The p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea4e5e9410953eba5a22693701a33bc
https://doi.org/10.1016/j.cardfail.2010.04.006
Zobrazit plný text záznamu
4
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
Autor: Mary E. Hanson, Harold E. Bays, Andrew M. Tershakovec, Arvind Shah, Steven R. Bird, Scott Conard, J. Lin, Lawrence A. Leiter
Publikováno v: Diabetes, Obesity and Metabolism. 12:210-218
Aim: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are both associated with increased risk for atherosclerotic coronary heart disease (CHD). Thus, it is useful to know the relative efficacy of lipid-altering drugs in these patient pop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6504e89b21088b7cadfde9a9408ae023
https://doi.org/10.1111/j.1463-1326.2009.01152.x
Zobrazit plný text záznamu
5
Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease
Autor: Steven R. Bird, Andrew M. Tershakovec, Mary E. Hanson, Joseph Rubino, Lawrence A. Leiter, Harold E. Bays, Joanne E. Tomassini, Scott Conard
Publikováno v: The American Journal of Cardiology. 102:1495-1501
The percentage of change from baseline in low-density lipoprotein (LDL) cholesterol after the addition of ezetimibe 10 mg to atorvastatin 40 mg was compared with uptitration to atorvastatin 80 mg. In this multicenter, double-blind, parallel-group stu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b29f3d4f2b1b6cbd6a6950d15b1f9a
https://doi.org/10.1016/j.amjcard.2008.09.076
Zobrazit plný text záznamu
6
Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company
Autor: Joseph Rubino, Robert S. Lowe, Harold E. Bays, Andrew M. Tershakovec, Joanne E. Tomassini, Lawrence A. Leiter, Steven R. Bird, Scott Conard
Publikováno v: The American Journal of Cardiology. 102:1489-1494
The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who did
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87d7a9ae0995f7aa1bff16f9b519cd91
https://doi.org/10.1016/j.amjcard.2008.09.075
Zobrazit plný text záznamu
7
Correlation of Measures of Pain, Function, and Overall Response
Autor: Steven S. Smugar, Eric A. Sheldon, Steven R. Bird, Andrew M. Tershakovec
Publikováno v: Spine. 33:533-538
Study design Assessment of correlation of measures of low back pain (LBP) using data pooled from 2 identical studies. Objective To assess the relative responsiveness of and correlation between various measures of LBP, including the Roland-Morris Disa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd21cb02b298f4de1207303a7b2609ef
https://doi.org/10.1097/brs.0b013e3181657d24
Zobrazit plný text záznamu
8
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
Autor: Brian Fitzgerald, Bernard R. Rubin, Joel M. Kremer, Steven S. Smugar, A. I. Sebba, Steven R. Bird, Clifton O. Bingham, K. O'Brien, Andrew M. Tershakovec, Gary E. Ruoff
Publikováno v: Rheumatology. 46:496-507
OBJECTIVE To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. METHODS Two multi-centre, 26-week, double-blind, plac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70cfcb318add4be2f6a9b6085edb16dd
https://doi.org/10.1093/rheumatology/kel296
Zobrazit plný text záznamu
9
Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity
Autor: Jonathan M. Edelman, Mark S. Dykewicz, Thomas B. Casale, Eli O. Meltzer, Carolyn M. Hustad, Evalyn Grant, William W. Busse, Steven R. Bird, Robert K. Zeldin
Publikováno v: Annals of Allergy, Asthma & Immunology. 96:60-68
Background Montelukast has proven efficacy in the treatment of chronic asthma and seasonal allergic rhinitis, but it has not been evaluated in the subpopulation of asthmatic patients with seasonal asthma symptoms. Objective To determine the effective
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac56145f292a934561105fee503f46d
https://doi.org/10.1016/s1081-1206(10)61041-1
Zobrazit plný text záznamu
10
Analgesic efficacy of rofecoxib compared with codeine/acetaminophen using a model of acute dental pain
Autor: Norman R. Bohidar, Thomas R. King, David J. Chang, Steven R. Bird
Publikováno v: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 100:e74-e80
To determine analgesic efficacy of a single oral dose of rofecoxib 50 mg compared with acetaminophen/codeine 600/60 mg, we conducted a double-blind, randomized, placebo- and active-comparator-controlled, parallel-group study.Patients (N = 390) experi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::658e166d2a977c6279f78c3fde2d72b8
https://doi.org/10.1016/j.tripleo.2005.04.026
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje